Outcome of pregnancy after organ transplantation: a retrospective survey in Italy

Abstract

The number of women who decide to have a child after organ transplantation has increased. We determined the outcomes of 67 pregnancies of women who had undergone kidney, liver or heart transplantation. All recipients had been maintained on immunosuppressive therapy before and during pregnancy. Pregnancy complications at term were observed in 17 out of 67 women (25%), hypertension being the most frequent complication (16.17%). Two transplant rejections were reported. Sixty‐eight infants were delivered (including one pair of twins); five women had two pregnancies at term. Twenty‐eight miscarriages (29.2%) were recorded. Of these 68 babies (including the pair of twins), 40 (58.8%) were born at term and 28 (41.2%) before term. The babies were followed‐up for 2 months to 13 years. According to our previous experience, our study shows that patients who have undergone organ transplantation can give birth to healthy infants as long as they are monitored accurately during pregnancy.

Pregnancy outcomes of liver transplant recipients: A systematic review and meta-analysis

“…Among the 638 citations that were initially retrieved from the 3 electronic database searches, 578 were found to be unique studies that qualified for abstract screening. After the screening, 18 full‐text articles were reviewed, of which 10 were excluded: 1 article that specifically studied the teratogenic effects of mycophenolate mofetil in 3 LT recipients and the effects of sirolimus in 2 LT recipients,17 2 review articles,18, 19 3 studies of multiorgan transplant recipients,20‐22 4 studies that did not involve post‐LT pregnancy outcomes,2, 23‐25 and 1 study of a duplicate/identical cohort 1. Ultimately, 8 studies were selected for inclusion (Fig.…”

Grossesse après transplantation rénale. Suivi obstétrical et retentissement sur le greffon rénal

“…Leur métabolite actif traverse le placenta avec une concentration foetale correspondant au dixième de la concentration maternelle avec un risque de 5 % d'insuffisance surrénalienne même à doses faibles [28,29]. Nous pensons, néanmoins, qu'il est nécessaire d'organiser une surveillance de ces nouveau-nés exposés in utero aux traitements immunosuppresseurs afin de déceler l'apparition d'é-ventuelles complications de ces traitements [26][27][28][29][30][31].…”

Unraveling the Role of Peptidyl-Prolyl Isomerases in Neurodegeneration

“…Using GPI-1046, it was shown that FKBP52 activity was required for growth cone guidance, but not for general axon growth. The authors raised concern that the use of FK506 and other IL may therefore disturb fetal nervous system development [137] but acknowledge that the use of specific inhibitors may have therapeutic relevance.…”